New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif® (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50^th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

Data include results from global Phase III trials of afatinib in different patient groups with advanced non-small cell lung cancer (NSCLC):

• LUX-Lung 3 and LUX-Lung 6 overall survival analysis (abstract #8004, oral presentation) comparing first-line afatinib to chemotherapy in patients with advanced NSCLC whose tumors have common epidermal growth factor receptor (EGFR) mutations
• LUX-Lung 5 (abstract #8019, poster session) evaluating treatment beyond disease progression with afatinib and paclitaxel versus investigator's choice of chemotherapy alone in patients with late-stage NSCLC whose disease has progressed after afatinib alone and have also failed several treatments, including chemotherapy, erlotinib or gefitinib

"Boehringer Ingelheim is proud to present at this ASCO meeting the results from several abstracts for GILOTRIF as well as other investigational compounds from our growing oncology pipeline," said Berthold Greifenberg, M.D., vice president, Clinical Development and Medical Affairs, Oncology, Boehringer Ingelheim Pharmaceuticals, Inc. "Here at Boehringer Ingelheim, we are committed to advancing the care of patients, and these data underscore our efforts to investigate our research and clinical development programs in a variety of cancer types."